The DOI matches its Crossref record; 102 of the 104 references it cites were found in a registry or an index.
Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults
Open accessAbstract
Objective Choices of pharmacologic therapies for pulmonary arterial hypertension (PAH) are ideally guided by high-level evidence. The objective of this guideline is to provide clinicians advice regarding pharmacologic therapy for adult patients with PAH as informed by available evidence.Methods This guideline was based on systematic reviews of English language evidence published between 1990 and November 2013, identified using the MEDLINE and Cochrane Library databases. The strength of available evidence was graded using the Grades of Recommendations, Assessment, Development, and Evaluation methodology. Guideline recommendations, or consensus statements when available evidence was insufficient to support recommendations, were developed using a modified Delphi technique to achieve consensus.Results Available evidence is limited in its ability to support high-level recommendations. Therefore, we drafted consensus statements to address many clinical questions regarding pharmacotherapy for patients with PAH. A total of 79 recommendations or consensus statements were adopted and graded.Conclusions Clinical decisions regarding pharmacotherapy for PAH should be guided by high-level recommendations when sufficient evidence is available. Absent higher level evidence, consensus statements based upon available information must be used. Further studies are needed to address the gaps in available knowledge regarding optimal pharmacotherapy for PAH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that most efficacious therapies for the treatment of PH involve targeting of NO signaling[48,49], it is clear that pulmonary vascular health is intimately tied to effective NO bioactivity.”
From Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health (2017) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,586
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Rosa, S. D., Samoni, S., Villa, G., & Ronco, C. (2017) · Blood Purification · doi:10.1159/000452650 · Cited by 5,040
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Hoeper, M. M., Humbert, M. J. C., Torbicki, A., Vachiéry, J., Barberà, J. A., Beghetti, M., Corris, P. A., Gaine, S., Gibbs, J. S. R., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,853
Bosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., KEOGH, A. M., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,718
Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. Μ., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,688
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D. B., Fleming, T. R., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,466
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,359
Cited by
Sorted by citations
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Pediatric Pulmonary Hypertension
Abman, S. H., Hansmann, G., Archer, S. L., Ivy, D. D., Adatia, I., Chung, W. K., Hanna, B. D., Rosenzweig, E. B., Raj, J. U., Cornfield, D. N., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000329 · Cited by 1,173
Update of EULAR recommendations for the treatment of systemic sclerosis
Kowal-Bielecka, O., Fransen, J., Avouac, J., Becker, M., Kulak, A., Allanore, Y., Distler, O., Clements, P., Cutolo, M., Czirjak, L., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209909 · Cited by 1,104
Pulmonary arterial hypertension: pathogenesis and clinical management
Thenappan, T., Ormiston, M. L., Ryan, J. J., & Archer, S. L. (2018) · BMJ · doi:10.1136/bmj.j5492 · Cited by 1,004
Ezekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., Giannetti, N., Grzeslo, A., Hamilton, P. G., Heckman, G. A., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.08.022 · Cited by 676
Pediatric Pulmonary Hypertension
Ivy, D. D., Abman, S. H., Barst, R. J., Berger, R. M. F., Bonnet, D., Fleming, T. R., Haworth, S. G., Raj, J. U., Rosenzweig, E. B., Schulze‐Neick, I., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.028 · Cited by 543
Management of Pulmonary Arterial Hypertension
McLaughlin, V. V., Shah, S. J., Souza, R., & Humbert, M. J. C. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.540 · Cited by 381
Management of interstitial lung disease associated with connective tissue disease
Mathai, S. C., & Danoff, S. K. (2016) · BMJ · doi:10.1136/bmj.h6819 · Cited by 337
Therapy for Pulmonary Arterial Hypertension in Adults
Klinger, J. R., Elliott, C. G., Levine, D. J., Bossone, E., Duvall, L. E., Fagan, K., Frantsve‐Hawley, J., Kawut, S. M., Ryan, J. J., Rosenzweig, E. B., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2018.11.030 · Cited by 301
Weatherald, J. C., Boucly, A., Chemla, D., Savale, L., Peng, M., Jevnikar, M., Jaïs, X., Taniguchi, Y., O’Connell, C., Parent, F., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029254 · Cited by 225
Koch, C. D., Gladwin, M. T., Freeman, B. A., Lundberg, J. O., Weitzberg, E., & Morris, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.015 · Cited by 186
Florentin, J., Coppin, E., Vasamsetti, S. B., Zhao, J., Tai, Y., Tang, Y., Zhang, Y., Watson, A. M. M., Sembrat, J., Rojas, M. M., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701287 · Cited by 160
The molecular targets of approved treatments for pulmonary arterial hypertension
Humbert, M. J. C., & Ghofrani, H. A. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-207170 · Cited by 155
Houde, M., Desbiens, L., & D’Orléans-Juste, P. (2016) · Advances in pharmacology · doi:10.1016/bs.apha.2016.05.002 · Cited by 127
The importance of patient perspectives in pulmonary hypertension
McGoon, M. D., Ferrari, P., Armstrong, I. J., Denis, M., Howard, L., Lowe, G., Mehta, S., Murakami, N., & Wong, B. A. (2018) · European Respiratory Journal · doi:10.1183/13993003.01919-2018 · Cited by 123
The Future of Lung Transplantation
Young, K. A., & Dilling, D. F. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.08.1036 · Cited by 127
The Nitric Oxide Pathway in Pulmonary Vascular Disease
Klinger, J. R., & Kadowitz, P. J. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.06.012 · Cited by 119
Price, L., Martinez, G. C., Brame, A., Pickworth, T., Samaranayake, C. B., Alexander, D. J., Garfield, B. E., Aw, T., McCabe, C., Mukherjee, B., et al. (2021) · British Journal of Anaesthesia · doi:10.1016/j.bja.2021.01.005 · Cited by 113
Anker, S. D., Schroeder, S., Atar, D., Bax, J. J., Ceconi, C., Cowie, M., Crisp, A., Dominjon, F., Ford, I., Ghofrani, H. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.516 · Cited by 108
Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases
Schopfer, F. J., Vitturi, D. A., Jorkasky, D. K., & Freeman, B. Α. (2018) · Nitric Oxide · doi:10.1016/j.niox.2018.06.006 · Cited by 93
Lindley, K. J., Merz, C. N. B., Asgar, A., Bello, N. A., Chandra, S., Davis, M. B., Gomberg‐Maitland, M., Gulati, M., Hollier, L. M., Krieger, E. V., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.026 · Cited by 102
Medeiros, B. C., Possick, J. D., & Fradley, M. G. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.01.004 · Cited by 89
Group III Pulmonary Hypertension
Klinger, J. R. (2016) · Cardiology Clinics · doi:10.1016/j.ccl.2016.04.003 · Cited by 84
Role of prostacyclin in pulmonary hypertension
Mitchell, J. A., Ahmetaj‐Shala, B., Kirkby, N. S., Wright, W. R., Mackenzie, L. S., Reed, D. M., & Mohamed, N. A. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.53 · Cited by 86
Lau, E., Tamura, Y., McGoon, M. D., & Sitbon, O. (2015) · European Respiratory Journal · doi:10.1183/13993003.01177-2015 · Cited by 82
Hillegass, E. A., Puthoff, M. L., Frese, E., Thigpen, M. T., Sobush, D. C., Auten, B., & for the Guideline Development Group (2015) · Physical Therapy · doi:10.1093/ptj/pzac057 · Cited by 82
Pulmonary arterial hypertension specific therapy: The old and the new
Zolty, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107576 · Cited by 75
The prostacyclin pathway in pulmonary arterial hypertension: a clinical review
del Pozo, R., Hernández‐González, I., & Subías, P. E. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1317599 · Cited by 76
Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension
Agüero, J., Ishikawa, K., Hadri, L., Santos‐Gallego, C. G., Fish, K. M., Kohlbrenner, E., Hammoudi, N., Kho, C., Lee, A., Ibáñez, B., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.049 · Cited by 75
Zelt, J. G. E., Sugarman, J. A., Weatherald, J. C., Partridge, A. C. R., Liang, J., Swiston, J. R., Brunner, N. W., Chandy, G., Stewart, D. J., Contreras-Domínguez, V., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.01552-2021 · Cited by 69
“Treat-to-close”: Non-repairable ASD-PAH in the adult
Bradley, E. A., Ammash, N. M., Martinez, S. C., Chin, K., Hebson, C. L., Singh, H. S., Aboulhosn, J., Grewal, J., Billadello, J. J., Chakinala, M. M., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.03.056 · Cited by 66
McGlothlin, D. P., Granton, J. T., Klepetko, W., Beghetti, M., Rosenzweig, E. B., Corris, P. A., Horn, E. M., Kanwar, M. K., McRae, K. M., Román, A., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.06.013 · Cited by 67
Humanistic and cost burden of systemic sclerosis: A review of the literature
Fischer, A., Zimovetz, E. A., Ling, C. S., Esser, D., & Schoof, N. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.09.010 · Cited by 60
Pulmonary Arterial Hypertension in Pregnancy
Ballard, W., Dixon, B., McEvoy, C. A., & Verma, A. (2020) · Cardiology Clinics · doi:10.1016/j.ccl.2020.09.007 · Cited by 60
Rashid, J., Patel, B., Nozik‐Grayck, E., McMurtry, I. F., Stenmark, K. R., & Ahsan, F. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.003 · Cited by 61
Classification and pathophysiology of pulmonary hypertension
Sysol, J. R., & Machado, R. F. (2018) · Continuing Cardiology Education · doi:10.1002/cce2.71 · Cited by 65
Atrial arrhythmias are associated with increased mortality in pulmonary arterial hypertension
Smith, B., Genuardi, M. V., Koczo, A., Zou, R. H., Thoma, F. W., Handen, A. L., Craig, E., Hogan, C. M., Girard, T. D., Althouse, A. D., et al. (2018) · Pulmonary Circulation · doi:10.1177/2045894018790316 · Cited by 55
Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
Sidharta, P. N., Treiber, A., & Dingemanse, J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0255-5 · Cited by 58
Liu, H.-L., Chen, X., Li, J.-R., Su, S., Ding, T., Shi, C., Jiang, Y., & Zhu, Z. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.03.031 · Cited by 54
Liu, C.-M., Shih, E. S. C., Chen, J.-Y., Huang, C.-H., Wu, I.-C., Chen, P.-F., Higa, S., Yagi, N., Hu, Y.-F., Hwang, M.-J., et al. (2022) · JACC: Asia · doi:10.1016/j.jacasi.2022.02.008 · Cited by 46
Trammell, A. W., Pugh, M. E., Newman, J. H., Hemnes, A. R., & Robbins, I. M. (2015) · Pulmonary Circulation · doi:10.1086/681264 · Cited by 46
Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension
Jain, S., Khera, R., Girotra, S. R., Badesch, D. B., Wang, Z., Murad, M. H., Blevins, A., Schmidt, G. A., Singh, S., & Gerke, A. K. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.08.1461 · Cited by 47
Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
Lian, T., Jiang, X., & Jing, Z. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s117277 · Cited by 45
Origin and production of inflammatory perivascular macrophages in pulmonary hypertension
Florentin, J., & Dutta, P. (2017) · Cytokine · doi:10.1016/j.cyto.2017.08.015 · Cited by 45
From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress
Franssen, C., Chen, H. S., Hamdani, N., & Paulus, W. J. (2015) · Heart · doi:10.1136/heartjnl-2015-307787 · Cited by 46
Shah, N. B., Mitchell, R. E., Proctor, S. T., Choi, L., DeClercq, J., Jolly, J. A., Hemnes, A. R., & Zuckerman, A. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217798 · Cited by 42
Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension
Keshavarz, A. A., Kadry, H., Alobaida, A., & Ahsan, F. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1729119 · Cited by 43
Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension
de Raaf, M. A., Beekhuijzen, M. E. W., Guignabert, C., Noordegraaf, A. V., & Bogaard, H. J. (2015) · Reproductive Toxicology · doi:10.1016/j.reprotox.2015.06.048 · Cited by 42
Pulmonary hypertension: diagnostic and therapeutic challenges
Fares, W. H., & Bazan, I. S. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s74881 · Cited by 43
Riociguat: A Novel New Drug for Treatment of Pulmonary Hypertension
Makowski, C. T., Rissmiller, R. W., & Bullington, W. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1592 · Cited by 40
Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia
Heresi, G. A., Platt, D. M., Wang, W., Divers, C., Joish, V. N., Teal, S. A., & Yu, J. S. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0399-1 · Cited by 39
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension
Mahmud, E., Behnamfar, O., Ang, L., Patel, M. P., Poch, D. S., & Kim, N. H. (2017) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2017.09.003 · Cited by 40
Chen, M., Shen, H., Zhu, L., Yang, H., Ye, P., Liu, P., Gu, Y., & Chen, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28370 · Cited by 37
Diekemper, R. L., Patel, S., Mette, S. A., Ornelas, J., Ouellette, D. R., & Casey, K. R. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.04.018 · Cited by 36
Corboz, M. R., Li, Z., Malinin, V., Plaunt, A. J., Konicek, D. M., Leifer, F., Chen, K., Laurent, C. E., Yin, H., Biernat, M., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242099 · Cited by 36
Steppan, J., Diaz-Rodriguez, N., Barodka, V. M., Nyhan, D. P., Pullins, E. H., Housten, T., Damico, R. L., Mathai, S. C., Hassoun, P. M., Berkowitz, D. E., et al. (2018) · Cureus · doi:10.7759/cureus.2072 · Cited by 35
Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
Rysz-Górzynska, M., Gluba-Brzózka, A., Sahebkar, A., Serban, M.-C., Mikhailidis, D. P., Ursoniu, S., Toth, P. P., Bittner, V., Watts, G. F., Lip, G. Y. H., et al. (2016) · Scientific Reports · doi:10.1038/srep30060 · Cited by 33
Bazan, I. S., Mensah, K. A., Rudkovskaia, A. A., Adonteng-Boateng, P., Herzog, E. L., Buckley, L. M., & Fares, W. H. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.11.020 · Cited by 33
Frost, A., Janmohamed, M., Fritz, J. S., McConnell, J. W., Poch, D. S., Fortin, T., Miller, C. E., Chin, K., Fisher, M., Eggert, M. S., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.09.003 · Cited by 32
Anderson, J. R., Nawarskas, J. J., & Henrie, A. M. (2015) · Core evidence · doi:10.2147/ce.s58457 · Cited by 31
Mandras, S. A., Kovács, G., Olschewski, H., Broderick, M. J., Nelsen, A. C., Shen, E., & Champion, H. C. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211006531 · Cited by 33
Sidharta, P. N., Krähenbühl, S., & Dingemanse, J. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1000859 · Cited by 30
Emerging therapeutics in pulmonary hypertension
Hensley, M. K., Levine, A. R., Gladwin, M. T., & Lai, Y. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00259.2017 · Cited by 30
Plasma 12‐ and 15‐Hydroxyeicosanoids are Predictors of Survival in Pulmonary Arterial Hypertension
Al‐Naamani, N., Sagliani, K. D., Dolnikowski, G. G., Warburton, R. R., Toksoz, D., Kayyali, U. S., Hill, N. S., Fanburg, B. L., Roberts, K. E., & Preston, I. R. (2016) · Pulmonary Circulation · doi:10.1086/686311 · Cited by 30
Aguirre‐Camacho, A., & Jiménez, B. M. (2018) · Psychosomatics · doi:10.1016/j.psym.2018.04.002 · Cited by 30
Pulmonary hypertension in patients with interstitial lung disease
Karampitsakos, Τ., Tzouvelekis, A., Chrysikos, S., Bouros, D. E., Tsangaris, I., & Fares, W. H. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.03.002 · Cited by 29
Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge
Roldan, T., Landzberg, M. J., Deicicchi, D. J., Atay, J. K., & Waxman, A. B. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.10.002 · Cited by 28
What’s new in the treatment of portopulmonary hypertension?
DuBrock, H. M., Channick, R. N., & Krowka, M. J. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1035647 · Cited by 27
How I treat patients with systemic sclerosis in clinical practice
Rossi, D., Zanatta, E., Marson, P., Sciascia, S., Polito, P., Roccatello, D., & Cozzi, F. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.018 · Cited by 27
New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension
Hill, N. S., Cawley, M. J., & Heggen, C. L. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.3-a.s3 · Cited by 27
Pulmonary Arterial Hypertension in Women
Memon, H. A., & Park, M. (2017) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-13-4-224 · Cited by 26
Treatment-Related Biomarkers in Pulmonary Hypertension
Swaminathan, A. C., Dusek, A. C., & McMahon, T. J. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0438tr · Cited by 26
Current trends in candidate selection, contraindications, and indications for lung transplantation
Arjuna, A., Olson, M. T., & Walia, R. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-2021-09 · Cited by 26
Evaluation and management approaches for scleroderma lung disease
Schoenfeld, S. R., & Castelino, F. V. (2017) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817713680 · Cited by 26
Magnesium Sulfate Mitigates the Progression of Monocrotaline Pulmonary Hypertension in Rats
Chang, C., Shih, H., Huang, I., Tsai, P., Chen, K.-Y., & Huang, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184622 · Cited by 26
Selexipag: A Review in Pulmonary Arterial Hypertension
Duggan, S. T., Keam, S. J., & Burness, C. B. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0209-9 · Cited by 25
Medical treatment update on pulmonary arterial hypertension
Enderby, C. Y., & Burger, C. D. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315590757 · Cited by 25
Langendam, M. W., Carrasco‐Labra, A., Santesso, N. A., Mustafa, R. A., Brignardello‐Petersen, R., Ventresca, M., Heus, P., Lasserson, T. J., Moustgaard, R., Brożek, J., et al. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.12.008 · Cited by 25
Qadus, S., Naser, A. Y., Ofori‐Asenso, R., Ademi, Z., Awawdeh, S. A., & Liew, D. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00553-6 · Cited by 29
Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
Gall, H. J., Vachiéry, J., Tanabe, N., Halank, M., Orozco‐Levi, M., Mielniczuk, L. M., Chang, M., Vogtländer, K., & Grünig, E. (2018) · Lung · doi:10.1007/s00408-018-0100-3 · Cited by 24
Zhang, Y.-J., Wang, N., Gu, Z., Wei, A., Cheng, A.-N., Fang, S., Du, H., Wang, L., & Zhang, G. (2019) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2019.03.02 · Cited by 23
Singh, V., Singh, S., Sharma, B., Bairwa, M. L., Gothi, D., Desai, U. D., Joshi, J. M., Talwar, D., Singh, A., Dhar, R., et al. (2020) · Lung India · doi:10.4103/lungindia.lungindia_275_20 · Cited by 22
Milks, M. W., Sahay, S., Benza, R. L., & Farber, H. W. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.12.005 · Cited by 23
Naing, P., Kuppusamy, H., Scalia, G. M., Hillis, G. S., & Playford, D. A. (2016) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.10.008 · Cited by 23
Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension
Ewert, R., Richter, M. J., Steringer‐Mascherbauer, R., Grünig, E., Lange, T. J., Opitz, C. F., Warnke, C., & Ghofrani, H. A. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1114-1 · Cited by 23
Fanous, S., & Janmohamed, M. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp170814 · Cited by 22
Interventional and Surgical Treatments for Pulmonary Arterial Hypertension
Stącel, T., Latos, M., Urlik, M., Nęcki, M., Antończyk, R., Hrapkowicz, T., Kurzyna, M., & Ochman, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153326 · Cited by 24
Burger, C. D., Pruett, J., Lickert, C. A., Berger, A., Murphy, B., & Drake, W. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.17228 · Cited by 22
Connective Tissue Disease–Associated Pulmonary Arterial Hypertension
Sung, Y. K., & Chung, L. S. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.01.003 · Cited by 22
Zhao, Q., Guo, N., Chen, J., Parks, D. C., & Tian, Z. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13481 · Cited by 21
Aerosolization of COVID-19 and Contamination Risks During Respiratory Treatments.
Benge, C. D., & Barwise, J. (2020) · PubMed Central · Cited by 21
Divers, C., Platt, D. M., Wang, E., Lin, J., Lingohr-Smith, M., & Mathai, S. C. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.1.92 · Cited by 21
Selexipag for the treatment of pulmonary arterial hypertension
Noel, Z. R., Kido, K., & Macaulay, T. E. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160798 · Cited by 21
Liu, P., Hsing, S.-C., Tsai, D., Lin, C. S., Lin, C.-S., Wang, C., & Fang, W. (2024) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-024-01225-4 · Cited by 20
Pulmonary Hypertension: Scientometric Analysis and Density-Equalizing Mapping
Götting, M., Schwarzer, M., Gerber, A., Klingelhöfer, D., & Groneberg, D. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169238 · Cited by 20
Managing the Patient with Pulmonary Hypertension
Chakinala, M. M., Duncan, M., & Wirth, J. A. (2016) · Cardiology Clinics · doi:10.1016/j.ccl.2016.04.008 · Cited by 19
Cowie, M., Filippatos, G. S., García, M. D. L. A. A., Anker, S. D., Baczyńska, A., Bloomfield, D. M., Borentain, M., Slot, K. B., Cronin, M., Doevendans, P. A., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.809 · Cited by 19
Agnihotri, V. V., Agrawal, Y. O., Goyal, S. N., Sharma, C., & Ojha, S. K. (2022) · Molecules · doi:10.3390/molecules27113490 · Cited by 22
Protective effect of Alpinetin on rats with chronic obstructive pulmonary disease
Su, Y., Tao, X., & Xu, J. (2020) · Food Science & Nutrition · doi:10.1002/fsn3.1952 · Cited by 19
An Update on the Management of Pulmonary Arterial Hypertension and the Pharmacist’s Role
Macaulay, T. E., Covell, M. B., & Pogue, K. T. (2015) · Journal of Pharmacy Practice · doi:10.1177/0897190015615902 · Cited by 19
Metadata
- Authors
- Taichman, D. B., Ornelas, J., Chung, L., Klinger, J. R., Lewis, S., Mandel, J., Palevsky, H. I., Rich, S., Sood, N., Rosenzweig, E. B., Trow, T. K., Yung, R., Elliott, C. G., & Badesch, D. B.
- Affiliations
- University of Pennsylvania (US)
- American College of Chest Physicians (US)
- VA Palo Alto Health Care System (US)
- Brown University (US)
- University of California San Diego (US)
- University of Chicago (US)
- The Ohio State University (US)
- Columbia University Irving Medical Center (US)
- Yale University (US)
- Johns Hopkins University (US)
- University of Utah (US)
- University of Colorado Denver (US)
- Corresponding author
- Ornelas, Joe
- ORCID
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 146
- Issue
- 2
- Pages
- 449-475
- ISSN
- 0012-3692 (ISSN-L)
- PMC
- PMC4137591
- OpenAlex
- W2157947374
- Cited by
- 256
- References
- 104
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 6 · 2023: 5 · 2022: 13 · 2021: 18 · 2020: 14 · 2019: 25 · 2018: 29 · 2017: 43 · 2016: 40 · 2015: 43 · 2014: 5
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- CHEST Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- pulmonary arterial hypertension, pharmacotherapy, adult patients, antihypertensive drugs, consensus statement, treatment guidelines, level of evidence
- MeSH terms
- Adult, Antihypertensive Agents, Delphi Technique, Humans, Hypertension, Pulmonary, Practice Guidelines as Topic, Consensus, Familial Primary Pulmonary Hypertension
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
